The effect of Spirulina platensis supplement in the treatment of coronavirus

Phase 3

• Conditions: COVID-19.; COVID disease; U07.02

• Registration Number: IRCT20210216050373N1
• Lead Sponsor: Tehran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 13 March 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 240

Inclusion Criteria

Male and female patients, age =18.
The patient is stable in condition and does not need resuscitation.
Signed informed consent form.
Definitive/clinical diagnosis of coronavirus.
The same treatment protocol (coronavirus) in both groups.
oxygen saturation =94%.

Exclusion Criteria

Pregnancy or lactation.
Any history of drug allergy.
Active, clinically significant chronic illness or human immunodeficiency virus disease.
Significant organ dysfunctions such as renal failure, liver dysfunction, CHF, or serious and unstable cardiac condition.
Underlying conditions that can affect patients' ability to provide adequate data.
Inability or refusal to sign the informed consent.
Any concurrent diseases or conditions which delay wound healing (cancer, vasculitis, immunosuppressive disorders, etc.)
Treatment with corticosteroids, Treatment with blood thinners(Warfarin), immunosuppressants, radiotherapy, or chemotherapy.
Receiving any investigational drug within 30 days prior to screening.
Abnormal liver enzymes and total bilirubin > 1.5 times of normal upper limit.
Specific and rare diseases such as people with HIV who are not receiving antiretroviral treatment, multiple sclerosis, SLE, rheumatoid arthritis, and PKU.
Observation of clinical signs not previously seen in patients with coronavirus and unusual complaints from patients.
Severe nausea after taking medication that does not improve with routine supportive treatment is considered as an exclusion criterion.

Study & Design

• Study Type: interventional
• Study Design: Not specified